The number people look for when evaluating a peptide COA: purity percentage.

The number people stop reading after: purity percentage.

That's the problem.

Purity tells you one thing. It is one of three distinct analytical questions, and the other two are at least as important for understanding what's actually in a vial.

We'll close with the only peer-reviewed study we could find that tested products bought from online sellers and measured all three. Its results are not what most people expect.

The Three Questions

Question 1: Identity Is this actually the compound named on the label?

Question 2: Purity Of the material detected, how much corresponds to the primary component?

Question 3: Quantity How much target material is actually present in the vial?

These are not interchangeable questions. A vial can show 99.8% purity and still:

Contain a completely different compound (high purity of the wrong molecule)
Contain substantially more or less than the labeled amount
Have a COA that belongs to a different batch entirely

Each failure mode is distinct. Each requires a different analytical approach to detect.

What HPLC Purity Actually Measures

High-Performance Liquid Chromatography (HPLC) is the standard analytical method behind most COA purity numbers. It works by separating the components of a sample and measuring how much of each component is present relative to the total.

The number you see — "99.2% purity" — means that 99.2% of the detected signal belongs to the primary peak. It does not tell you:

What that primary peak actually is
Whether its molecular mass matches the compound on the label
Whether its structural features are correct
How much of it is present in absolute terms (mg or mcg)

There is a further wrinkle worth understanding. Most peptide HPLC purity is measured by UV absorbance, and the response depends on what absorbs at the detection wavelength. Impurities with weak or absent chromophores are under-represented in the area percentage — sometimes invisible to it. So the reported purity is not merely a partial answer to the wrong question; it can also flatter the sample it does describe.

A sample with 99.2% purity of the wrong molecule produces a beautiful chromatogram that answers nothing you needed to know.

Why Identity Requires Different Tools

Confirming molecular identity requires methods that can characterize what the molecule actually is — not just how much of it is there.

Mass spectrometry (MS) — measures molecular mass. The intact mass of a peptide is highly specific to its sequence. If the reported mass doesn't match the expected molecular weight of the compound, something is wrong. High-resolution instruments (such as Orbitrap LC-HRMS/MS) routinely achieve mass accuracy in the low parts-per-million range or better.

MS/MS fragmentation — breaking the molecule apart and identifying the fragments. Fragment patterns are sequence-specific. Multiple fragment ions matching the expected sequence is much stronger evidence of identity than intact mass alone.

Nuclear Magnetic Resonance (NMR) — provides structural information based on the chemical environment of atoms in the molecule. ¹H NMR can confirm structural features including modifications, bridges, and conjugated moieties that mass spec alone may not fully resolve.

For complex engineered peptides — those with fatty acid conjugates, non-standard amino acids, or structural bridges — the combination of multiple orthogonal methods, each measuring a different physical property, provides convergent evidence that identity is confirmed.

The principle: don't ask the molecule one question. Ask it several different ways and see if the answers align.

Why Quantity Requires a Separate Measurement — and Why Weighing Doesn't Work

HPLC purity is a relative measurement: what percentage of detected signal belongs to the primary peak. It is not an absolute measurement of how much compound is present in the vial.

A vial labeled "10 mg BPC-157" at 99% purity could contain 10 mg, or 5 mg, or 15 mg. The purity figure is silent on which.

Here is the part that surprises people: you cannot answer this by weighing the powder.

Synthetic peptides are typically supplied as lyophilized trifluoroacetate (TFA) salts, and they are hygroscopic — they pull water out of the air. The mass on the balance therefore includes water, TFA counter-ions, and residual salts, none of which HPLC-UV detects and none of which are the peptide. Weighing systematically overstates how much peptide is present.

Determining actual net peptide content requires a method built for it:

Amino acid analysis — hydrolyze the peptide and quantify the constituent amino acids
Elemental (CHN) analysis — measure carbon, hydrogen and nitrogen content directly
Quantitative HPLC against a characterized reference standard — comparison to a material of known concentration

"Purity" and "net peptide content" are two different numbers on a well-built COA. A certificate that reports only the first has not answered the quantity question.

What Happened When Someone Actually Tested the Market

Most discussion of peptide quality is anecdotal. There is one peer-reviewed study that bought products from online sellers without a prescription and ran the full analytical workup, and its results are worth reading carefully (Ashraf AR, Mackey TK, Vida RG, et al. Journal of Medical Internet Research. 2024).

Researchers analyzed semaglutide products purchased from online sellers. What they found:

Measurement	Result
Labeled content vs. actual	+28.6%, +33.6%, +38.7% above label
Purity	7.7% – 14.4% (against a claimed 99%)
Endotoxin	Present in all samples (2.16–8.95 EU/mg)
Viable microorganisms	None detected

Read that table twice, because it inverts the assumption most people bring to this topic.

The vials were not under-filled. They were substantially over-filled — by roughly a third. And the purity was not 99% as claimed; it was under 15%. A buyer measuring a dose by volume, trusting the label, would have been administering materially more total material than intended, most of which was not the compound they thought they were buying.

The documented risk in this market is not primarily that you get less than you paid for. It is that quantity and purity fail in opposite directions at the same time, and no single number on a certificate would have told you.

That is the entire argument of this post, demonstrated with real measurements: purity, identity and quantity are independent questions, and answering one tells you nothing reliable about the other two.

The COA Itself Is Evidence, Not Proof

A certificate of analysis is a document. Documents can be accurate and verifiable, accurate but belonging to a different batch, or unreliable.

The batch verification question matters most: does the COA's batch number match the batch you received? A legitimate certificate issued in January for a different batch is not valid documentation for material purchased in August.

A note on a claim we decided not to make. In researching this piece we repeatedly encountered the assertion that COAs are circulating attributed to laboratories that never issued them. It is a widely repeated claim. We were unable to trace it to any regulatory action, court filing, or investigative reporting — every source we found led back to vendor and affiliate marketing content, which is not a standard we're willing to cite. So we are not asserting it. If credible documentation exists, we'll report it. A post about verification standards should be willing to apply them to itself.

What we can say without qualification is that a certificate is a claim, and claims are verifiable or they are not. The questions to ask about any COA:

Can the issuing laboratory be contacted to verify this specific report?
Does the batch number on the COA match the batch number on the product you received?
Was identity tested — not just purity?
Was net peptide content measured, or only relative purity?
What analytical methods were used, and are the raw data available?

A "99.8% pure" number on a professionally formatted PDF does not automatically answer any of these.

Why This Matters More for Some Compounds

The quality verification problem varies in severity across the market. Several factors raise the risk:

Novelty — newer compounds have less established analytical baseline data. A laboratory needs a characterized reference standard to correctly analyze a sample. For compounds only recently available, reference standards may be less widely available, less well-characterized, or easier to substitute incorrectly.

Price — higher-value compounds create greater financial incentive to cut corners or substitute cheaper material. The incentive scales with the price differential between legitimate and fraudulent material.

Structural complexity — engineered peptides with fatty acid conjugates, non-standard amino acids, or structural modifications are harder to analyze correctly with basic HPLC. The risk of analytical error, including use of the wrong reference standard, increases with molecular complexity.

For newer, more expensive, structurally complex compounds, the analytical bar needs to be higher than for older, simpler, well-characterized peptides. This is also why regulatory status and evidence base are worth tracking alongside analytical quality — they tend to move together.

The Analytical Methods That Address Each Question

Question	Methods
Identity	Mass spectrometry (intact mass), MS/MS fragmentation, NMR (¹H, HSQC, COSY)
Purity	HPLC (relative, area percent)
Net peptide content	Amino acid analysis, elemental (CHN) analysis, quantitative HPLC vs. reference standard
Endotoxin	Bacterial endotoxins testing (LAL, or recombinant Factor C)
Elemental impurities	ICP-MS or ICP-OES, per USP <233> / ICH Q3D

Two notes on that table. Bacterial endotoxins testing is no longer synonymous with LAL — recombinant Factor C is an accepted compendial alternative, and the broader term is the accurate one. And elemental impurity testing permits ICP-OES as well as ICP-MS; both are validated compendial options.

For the most complete picture, orthogonal methods — multiple analytical approaches measuring different physical properties — provide convergent evidence far stronger than any single test.

What This Means for Anyone Tracking a Protocol

PeptidesGPT's approach to this space is educational. We don't sell compounds and we don't endorse vendors.

What we do endorse is the principle that tracking your response — body composition, bloodwork, daily check-ins, energy, mood, recovery — creates the data you need to make evidence-based decisions about what you're taking and whether it's working.

The study above is the practical case for it. If the material in a vial can be a third more than the label says at under 15% purity, then the relationship between what you intended to take and what actually entered your body is not something you can assume. It is something you observe, over time, in your own data.

If you're running a protocol and your response doesn't match what the literature would predict — including how it changes over the length of a cycle — that's a data point. It doesn't prove a quality problem, but it raises a hypothesis worth investigating with your provider.

Data is how you know. Without it, you're guessing.

→ Start tracking at PeptidesGPT.com

Sources:

Ashraf AR, Mackey TK, Vida RG, et al. "Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription." Journal of Medical Internet Research. 2024. doi:10.2196/65440
FDA: Analytical Procedures and Methods Validation for Drugs and Biologics — final guidance, July 2015
ICH Q2(R2): Validation of Analytical Procedures — ICH Step 4 adopted November 2023; FDA final guidance March 2024
ICH Q14: Analytical Procedure Development — companion guideline to Q2(R2)
USP General Chapter <233>, Elemental Impurities — Procedures; ICH Q3D
Olsen JV, et al. "Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection." Molecular & Cellular Proteomics. 2005

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice or legal advice. Always consult a licensed healthcare provider before making decisions about your health or protocol.